InsiderTrades.com logo
Protect Yourself While There’s Still Time …
From Weiss Ratings   |   Ad
The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.
4 simple steps to protect your privacy and money before it’s too late.

Robert Waltermire Biography and Net Worth

VP of Madrigal Pharmaceuticals
  • LinkedIn
  • Phone
  • Email
  • Website


Dr. Robert E. Waltermire Ph.D. is the Chief Pharmaceutical Devel. Officer at Madrigal Pharmaceuticals Inc.

What is Robert E. Waltermire's net worth?

The estimated net worth of Robert E. Waltermire is at least $1.10 million as of December 13th, 2023. Dr. Waltermire owns 5,667 shares of Madrigal Pharmaceuticals stock worth more than $1,095,601 as of April 27th. This net worth approximation does not reflect any other investments that Dr. Waltermire may own. Learn More about Robert E. Waltermire's net worth.

How do I contact Robert E. Waltermire?

The corporate mailing address for Dr. Waltermire and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at [email protected]. Learn More on Robert E. Waltermire's contact information.

Has Robert E. Waltermire been buying or selling shares of Madrigal Pharmaceuticals?

Robert E. Waltermire has not been actively trading shares of Madrigal Pharmaceuticals during the past quarter. Most recently, Robert E. Waltermire sold 2,500 shares of the business's stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $225.40, for a transaction totalling $563,500.00. Following the completion of the sale, the vice president now directly owns 5,667 shares of the company's stock, valued at $1,277,341.80. Learn More on Robert E. Waltermire's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Richard Levy (Director), Brian Lynch (SVP), Remy Sukhija (Sr. VP & Chief Commercial Officer), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, Madrigal Pharmaceuticals insiders bought shares 4 times. They purchased a total of 226,067 shares worth more than $43,382,043.47. During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 154,796 shares worth more than $33,116,646.13. The most recent insider tranaction occured on April, 8th when CMO Rebecca Taub sold 2,676 shares worth more than $658,269.24. Insiders at Madrigal Pharmaceuticals own 23.9% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 4/8/2024.

Robert E. Waltermire Insider Trading History at Madrigal Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/13/2023Sell2,500$225.40$563,500.005,667View SEC Filing Icon  
See Full Table

Robert E. Waltermire Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows Robert E Waltermire's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $193.33
Low: $189.00
High: $195.58

50 Day Range

MA: $243.29
Low: $193.33
High: $283.23

2 Week Range

Now: $193.33
Low: $119.76
High: $322.67

Volume

453,241 shs

Average Volume

387,373 shs

Market Capitalization

$3.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Protect Yourself While There’s Still Time …
From Weiss Ratings   |   Ad
The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.
4 simple steps to protect your privacy and money before it’s too late.